HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the Company’s Board of Directors has approved an increase in its stock repurchase program authorizing the repurchase of up to a total of $100 million of the Company’s common stock. The Company was previously authorized to repurchase up to $25 million of its stock.
